China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

China Pharma Holdings (CPHI) posted Convertible Debt of $4.8 million for Q2 2022, down 4.04% on a QoQ basis from $5.0 million in Q1 2022.

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022) Analysis & Trends

China Pharma Holdings' Convertible Debt history runs 2 years deep, the most recent figure standing at $4.8 million for Q2 2022.

Quarterly Convertible Debt changed N/A year-over-year to $4.8 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $4.8 million (changed N/A YoY) and the FY2021 annual result came in at $5.2 million, changed N/A from the prior year.
Convertible Debt was $4.8 million for Q2 2022 at China Pharma Holdings, down from $5.0 million in the prior quarter.
Across five years, Convertible Debt topped out at $5.2 million in Q4 2021 and bottomed at $4.8 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	China Pharma Holdings	629,344.02	460,870.02	285,487.00

Download Data